Zur inhalativen Antibiotika-Therapie bei Patienten mit zystischer Fibrose und Pseudomonas-Befall [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]

Details

Serval ID
serval:BIB_C39D1DD2A9EA
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Zur inhalativen Antibiotika-Therapie bei Patienten mit zystischer Fibrose und Pseudomonas-Befall [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection]
Journal
Schweizerische Medizinische Wochenschrift
Author(s)
Mordasini C., Aebischer C.C., Schoch O.D.
ISSN
0036-7672
Publication state
Published
Issued date
1997
Peer-reviewed
Oui
Volume
127
Number
21
Pages
905-910
Language
german
Notes
Publication types: English Abstract ; Journal Article ; Review
Abstract
Treating chronic Pseudomonas infection of the bronchial tree is a very important part of the treatment strategy in patients with cystic fibrosis. There are only a few antibiotics which are effective against pseudomonas. Many of them soon lead to bacterial resistance (e.g. fluoro-quinolones). Inhaling antibiotics produces high sputum concentrations and low systemic toxicity. Tolerance is good and resistance rare. Several clinical studies, some of them doubleblind placebo controlled, have shown a positive effect of inhaled antibiotics on symptoms, on frequency of necessary i.v. therapies and also on pulmonary function. Most commonly aminoglycosides (tobramycin) and colistin, which is not yet registered in Switzerland, are used. The main indication is chronic therapy of Pseudomonas infection.
Keywords
Administration, Inhalation, Anti-Bacterial Agents, Bronchitis, Colistin, Cystic Fibrosis, Humans, Microbial Sensitivity Tests, Pseudomonas Infections, Tobramycin
Pubmed
Web of science
Create date
28/01/2008 11:01
Last modification date
20/08/2019 16:38
Usage data